Skip to main content
Biocorp logo

Biocorp — Investor Relations & Filings

Ticker · ALCOR ISIN · FR0012788065 LEI · 969500TKUAME6031UQ32 PA Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2016-09-29 Interim / Quarterly Rep…
Country FR France
Listing PA ALCOR

About Biocorp

https://biocorpsys.com

Biocorp designs, develops, and manufactures medical devices and drug delivery systems for the pharmaceutical industry. The company specializes in combining precision engineering with connected technologies to improve patient treatment adherence and outcomes. Its portfolio includes both connected and non-connected devices, such as smart caps for inhalers (Inspair), pen injectors, and systems for drug reconstitution and safety. Biocorp manages the entire value chain, from research and development to manufacturing and final packaging, leveraging its expertise in plastics processing and advanced technological innovation. Since October 2023, Biocorp has been a subsidiary of Novo Nordisk.

Recent filings

Filing Released Lang Actions
Rapport financier semestriel
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL 2016' (2016 Half-Year Financial Report) for BIOCORP. It contains comprehensive financial statements (Balance Sheet, Income Statement, Cash Flow Statement) for the period ending June 30, 2016, along with management's analysis of the activity and results. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report. H1 2016
2016-09-29 French
Communiqués de mise à disposition de documents / Modalités de mise à disposition du rapport financier semestriel
Report Publication Announcement Classification · 1% confidence The document is a press release ('Communiqué de presse') dated September 29, 2016, announcing that the company has made its 'rapport financier semestriel au 30 juin 2016' (half-year financial report as of June 30, 2016) available to the public and filed it with the AMF (Autorité des Marchés Financiers). Key indicators: 1. It explicitly mentions the availability of a 'rapport financier semestriel' (half-year financial report). 2. The document itself is short (2572 chars) and primarily serves to announce the publication and provide a link to the actual report. 3. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published points towards a Report Publication Announcement (RPA) rather than the comprehensive report itself (which would be classified as IR). Therefore, the most appropriate classification is Report Publication Announcement (RPA).
2016-09-29 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces a partnership between BIOCORP and Aguettant regarding a project for Parkinson's disease treatment improvement. It details the collaboration, the technology involved (APOKONNECT, APOKINON®, Easylog), project timelines, and quotes company CEOs. This format—a formal announcement of a business development, partnership, or significant operational update, issued as a press release—does not align with the specific regulatory filings like 10-K, IR, ER, or DEF 14A. Since it is a general business announcement that doesn't fit the specific categories (like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS)), the most appropriate classification is the general regulatory/news announcement fallback category, RNS (Regulatory Filings), as it functions as a broad corporate disclosure.
2016-09-27 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a partnership between BIOCORP and Laboratoire Aguettant regarding a project (APOKONNECT) for Parkinson's disease management. It details the collaboration, the technology involved (Easylog), and quotes the CEOs. This format—a formal announcement of a business development or partnership, issued as a press release—does not fit the specific financial reporting categories like 10-K, IR, ER, or AR. It is not a proxy statement (DEF 14A), a management discussion (MDA), or a capital change (CAP). Since it is a general, non-standard regulatory announcement detailing a strategic business development, the most appropriate fallback category is Regulatory Filings (RNS), as it serves as a general public disclosure that doesn't fit the highly specific financial/governance codes provided.
2016-09-27 French
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse Information règlementée Contrat de liquidité" and specifically announces the semi-annual balance sheet ("Bilan semestriel") of a liquidity contract managed by TSAF, detailing the number of shares and cash held as of June 30, 2016, compared to December 31, 2015. This is a specific regulatory disclosure concerning market making/liquidity provision, which is not explicitly covered by the main categories like 10-K, ER, or IR. Since it is a formal, regulated announcement concerning market operations and financial instruments (liquidity contract), and it doesn't fit into specific categories like Director's Dealing (DIRS), Share Issue (SHA), or Dividend (DIV), the most appropriate fallback category is Regulatory Filings (RNS), as it is a formal regulatory communication that doesn't match the other specific definitions. The document length is short (2819 chars), suggesting it is an announcement rather than a full report.
2016-07-12 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release ("Communiqué de presse") announcing that BIOCORP received an award ("Product Line Strategy Leadership") from Frost & Sullivan. It details the award criteria and the company's achievements. This type of announcement, which communicates general positive news, awards, or minor operational updates that do not fit into specific financial reporting categories (like 10-K, ER, or IR), is best classified as a general Regulatory Filing or Announcement. Since there is no specific category for 'Award Announcement' and it is not a formal financial report, a management change, or a transaction report, the most appropriate fallback category is Regulatory Filings (RNS). The document length (5630 chars) is substantial enough that it is not merely a placeholder for a larger report (ruling out RPA).
2016-05-09 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.